12:00 AM
May 28, 2012
 |  BioCentury  |  Emerging Company Profile

iTeos: Disabling tumor immune escape

iTeos developing small molecules to block tumor-mediated immunosuppression

Tumor cells exploit many signaling pathways to avoid detection by the host immune system, thereby limiting the potential of cancer immunotherapies. iTeos Therapeutics S.A. is developing small molecule immunomodulators that block these escape pathways, which could potentially boost and prolong the effects of cancer vaccines.

iTeos spun out of the Ludwig Institute for Cancer Research Ltd. (LICR) and the de Duve Institute at the Université catholique de Louvain last August to translate the LICR's scientific assets into immunomodulatory cancer therapies.

iTeos initially will focus on pancreatic, liver, lung and colorectal cancers. The company is pursuing three targets, two of which have been disclosed: tryptophan 2,3-dioxygenase (TDO2; TDO) and indoleamine 2,3-dioxygenase (INDO; IDO). The company has exclusive rights to the targets from LICR and could receive rights to future targets discovered at the institute.

The rationale for targeting IDO and...

Read the full 705 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >